QDDresearch

METRO INC. MRU

Consumer StaplesFood & Drug RetailingCanada

Last close 98.18 CAD on Nov 3, 2026, +1.1% year to date

Quant rating

Quant rating C Rank 10 of 21 in Consumer Staples
  1. Growth B 4 of 21
  2. Valuation C 14 of 21
  3. Quality B 6 of 21
  4. Revisions C 9 of 21
  5. Momentum B 8 of 21

Wall Street consensus Hold (2.73)Average target 101.90 CAD +3.8%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Growth and profitability fiscal year ends September 30

Growth and profitability by fiscal year
202520242023202220215Y avg
Revenue (mil)22,00721,22020,72518,88918,283–
Revenue growth3.7%2.4%9.7%3.3%1.6%4.1%
EPS (basic, normalized)4.774.304.303.823.44–
EPS growth10.9%0.0%12.6%11.0%––
Gross margin19.9%19.7%19.7%20.0%20.0%19.9%
Net margin4.6%4.4%4.9%4.5%4.5%4.6%
ROE14.5%13.4%15.1%13.0%13.1%13.8%
Balance sheet, last quarter
Cash & short-term investments (mil)49.9
Current ratio1.43x
Long-term debt (mil)4,641
Net debt (mil)4,916
Total equity (mil)6,960
Net debt / equity0.71x
Net debt / EBITDA2.36x

Estimates and valuation

Consensus estimates and implied multiples
Sales (mil)EBITDA (mil)EPS
Fiscal yearMean est.GrowthEV/SalesMean est.GrowthEV/EBITDAMean est.GrowthP/E
2025 actual 22,007+3.7%1.2x 2,083+4.9%12.2x 4.77+10.9%20.6x
2026 22,536+2.4%1.1x 2,040−2.0%12.4x 4.56−4.3%21.5x
2027 23,401+3.8%1.1x 2,269+11.2%11.2x 5.43+18.9%18.1x
2028 24,385+4.2%1.0x 2,404+5.9%10.5x 5.94+9.4%16.5x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
SalesEPS
Fiscal yearEstimate (mil)1M3M6MEstimate1M3M6M
202622,5360.0%−0.3%−0.8%4.56−0.3%−5.4%−10.7%
202723,401−0.1%−0.1%−0.2%5.43−0.6%−2.0%−3.3%
202824,385−0.2%+0.2%+0.1%5.94−0.5%+0.1%−2.2%

Earnings surprises EPS beat in 2 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter endedMar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales reported (mil)4,6566,6524,9385,1174,9106,8715,1095,2865,1136,970
Sales mean (mil)4,6626,6034,8635,1354,8616,9245,1165,2745,0806,913
Surprise−0.1%+0.7%+1.5%−0.3%+1.0%−0.8%−0.1%+0.2%+0.6%+0.8%
EPS reported0.911.351.021.101.021.521.131.161.111.24
EPS mean0.891.340.991.091.021.531.101.201.111.24
Surprise+2.1%+0.8%+3.3%+1.1%−0.4%−0.8%+2.7%−3.1%−0.2%+0.3%

Peer comparison Food & Drug Retailing

Peers in the same industry group, by market capitalization
CompanyMarket capNet debt/EBITDANet marginP/BFY1 P/EFY2 P/EFY1 EV/EBITDAFY2 EV/EBITDA
MRU METRO INC.20.4B2.36x4.6%2.95x21.5x18.1x12.4x11.2x
L Loblaw Companies Ltd79.9B2.09x4.0%7.30x27.0x24.1x12.7x11.9x
WN George Weston Limited40.6B3.55x1.6%9.00x23.0x19.7x8.8x8.2x
CASY Caseys General Stores Inc34.5B1.29x4.1%6.01x31.1x28.4x16.3x15.0x
TBBB BBB Foods Inc.11.2B8.10x−3.6%23.92x−64.1x−432.3x42.7x29.0x
ACI Albertsons Companies, Inc.8.7B2.32x0.3%4.41x7.7x8.0x4.3x4.4x
Mean3.28x1.8%8.93x7.7x−55.7x16.2x13.3x
Median2.34x2.8%6.66x22.3x18.9x12.6x11.5x

Technical analysis

  • 1M+10.7%
  • 3M+6.3%
  • 1Y+6.9%
  • 3Y+40.8%

Financial statements in millions of CAD

Income statement, METRO INC., fiscal years, most recent first
202520242023202220212020
Total revenue22,00721,22020,72518,88918,28317,998
Cost of revenue17,63617,04116,64215,10614,62814,416
Gross profit4,3704,1794,0823,7833,6553,582
Selling, general & administrative expenses––––1,3901,348
Research & development––––––
Depreciation/amortization594570525503478462
Interest expense (income), operating–––0.50.60.6
Unusual expense (income)24.414.0−4.244.807.5
Other operating expenses2,2872,1992,1171,964533543
Operating income1,4641,3961,4441,2711,2541,221
Net interest income (expense)−151−152−126−117−129−133
Gain (loss) on sale of assets––––––
Other non-operating income (expense)7.16.02.9−0.6−4.6−4.2
Net income before taxes1,3201,2501,3221,1541,1211,084
Provision for taxes301318303304295288
Minority interest−2.5−2.9−4.0−3.4−2.7−1.2
Equity in affiliates––––––
U.S. GAAP adjustment––––––
Net income before extraordinary items1,0179291,015846823795
Extraordinary items––––––
Net income1,0179291,015846823795
EBIT, normalized1,4881,4281,4401,3161,3591,232
EBITDA, normalized2,0831,9981,9651,8191,8361,694
Basic EPS, normalized4.774.304.303.823.44–

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 3, 2026 after market close.